NetraMark Advances Clinical Trials with New AI Contract
Company Announcements

NetraMark Advances Clinical Trials with New AI Contract

Netramark Holdings Inc (TSE:AIAI) has released an update.

NetraMark Holdings Inc., a leader in AI-driven clinical trial analytics, has secured a fourth contract with a major biopharmaceutical firm to enhance trial insights using their proprietary NetraAI technology. The AI will analyze trial data to improve patient selection and identify subpopulations affected by treatments, aiming to make trials more efficient and potentially accelerate patient access to therapies. This collaboration highlights NetraMark’s growing influence in transforming clinical trial analysis and patient segmentation.

For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskNetraMark Appoints Oncology Expert P.J. Haley to Board
TipRanks Canadian Auto-Generated NewsdeskNetraMark Unveils New Suite to Revolutionize Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskNetraMark’s Q3 Success with AI Clinical Trial Analytics
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App